NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $59.99 -0.89 (-1.46 %) (As of 01/17/2020 04:00 PM ET) Add Compare Today's Range$59.49Now: $59.99▼$61.6750-Day Range$39.12MA: $44.97▼$61.3652-Week Range$35.41Now: $59.99▼$74.50Volume48,252 shsAverage Volume848,234 shsMarket Capitalization$3.47 billionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE Previous Symbol CUSIPN/A CIK1515673 Webhttp://www.ultragenyx.com/ Phone415-483-8800Debt Debt-to-Equity Ratio0.04 Current Ratio6.79 Quick Ratio6.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$51.49 million Price / Sales67.31 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book4.98Profitability EPS (Most Recent Fiscal Year)($7.39) Net Income$-197,610,000.00 Net Margins-470.18% Return on Equity-52.16% Return on Assets-44.50%Miscellaneous EmployeesN/A Outstanding Shares57,771,000Market Cap$3.47 billion Next Earnings Date2/18/2020 (Estimated) OptionableOptionable Receive RARE News and Ratings via Email Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RARE Rates by TradingView Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.71) by $0.25. The biopharmaceutical company had revenue of $25.80 million for the quarter, compared to the consensus estimate of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The firm's revenue for the quarter was up 119.4% compared to the same quarter last year. During the same period last year, the business posted ($1.74) EPS. View Ultragenyx Pharmaceutical's Earnings History. When is Ultragenyx Pharmaceutical's next earnings date? Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical. What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million. What price target have analysts set for RARE? 11 brokers have issued 12 month price targets for Ultragenyx Pharmaceutical's stock. Their forecasts range from $59.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $73.55 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical. What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical. What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock? Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock: 1. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019) 2. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults, with X-linked hypophosphatemia (XLH) in the United States. The company looks forward to expand the global commercial reach of its approved therapies in 2019. It also expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders in the year. Ultragenyx continues to advance the two gene therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency — with additional data expected to be released in 2019. However, Since Ultragenyx is a newly commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have widened ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2019) Has Ultragenyx Pharmaceutical been receiving favorable news coverage? News stories about RARE stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Ultragenyx Pharmaceutical. Are investors shorting Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical saw a increase in short interest in December. As of December 31st, there was short interest totalling 6,500,000 shares, an increase of 6.2% from the December 15th total of 6,120,000 shares. Based on an average daily trading volume, of 531,700 shares, the days-to-cover ratio is currently 12.2 days. Approximately 12.1% of the shares of the stock are short sold. View Ultragenyx Pharmaceutical's Current Options Chain. Who are some of Ultragenyx Pharmaceutical's key competitors? Some companies that are related to Ultragenyx Pharmaceutical include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Horizon Therapeutics (HZNP). What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Netflix (NFLX), Portola Pharmaceuticals (PTLA), Gilead Sciences (GILD), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), Palo Alto Networks (PANW), Intercept Pharmaceuticals (ICPT), TG Therapeutics (TGTX) and Esperion Therapeutics (ESPR). Who are Ultragenyx Pharmaceutical's key executives? Ultragenyx Pharmaceutical's management team includes the folowing people: Emil D. Kakkis, President, Chief Executive Officer & DirectorWladimir Hogenhuis, Chief Operating OfficerShalini Sharp, Chief Financial Officer & Executive Vice PresidentDennis Karl Huang, Chief Technical Operations Officer & Senior VPEric Crombez, Chief Medical Officer How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $59.96. How big of a company is Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical has a market capitalization of $3.46 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical. What is Ultragenyx Pharmaceutical's official website? The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected] MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 697 (Vote Outperform)Underperform Votes: 341 (Vote Underperform)Total Votes: 1,038MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: Learning About the VIX - Volatility Index
